View by Specialty

Trending

PC0125Qi_Graphic_01_WEB
January 10, 2025
3 min read
Save

Drinking coffee in the morning reduces the risk for death

Inflammatory Bowel Disease News

SPONSORED CONTENT
January 17, 2025
2 min read
Save
Medicare selects 15 drugs for second round of price negotiations, including semaglutide

Medicare selects 15 drugs for second round of price negotiations, including semaglutide

CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS.

SPONSORED CONTENT
January 16, 2025
3 min read
Save

IBD drug market rattles as Lilly’s Omvoh nabs FDA approval for second IL-23p19 in Crohn’s

IBD drug market rattles as Lilly’s Omvoh nabs FDA approval for second IL-23p19 in Crohn’s

The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second interleukin-23p19 specific inhibitor approved for both major types of inflammatory bowel disease, Lilly reported.

SPONSORED CONTENT
January 06, 2025
2 min read
Save

Long term autoimmune, autoinflammatory disease risk significantly higher after COVID-19

Long term autoimmune, autoinflammatory disease risk significantly higher after COVID-19

SARS-CoV-2 infection, especially a severe case or without vaccination, significantly increases the long-term risk for developing autoimmune and autoinflammatory connective tissue diseases, according to data published in JAMA Dermatology.

Trending

PC0125Qi_Graphic_01_WEB
January 10, 2025
3 min read
Save

Drinking coffee in the morning reduces the risk for death

SPONSORED CONTENT
December 26, 2024
4 min read
Save

Biosimilar boom set to expand treatment landscape for IBD, inflammatory diseases in 2025

Biosimilar boom set to expand treatment landscape for IBD, inflammatory diseases in 2025

The expansion of safe and effective FDA-approved biosimilars for inflammatory bowel disease set to launch in early 2025 may improve access to care, with the potential to reduce health care costs and revolutionize the treatment landscape.

SPONSORED CONTENT
December 18, 2024
1 min read
Save

Celltrion's Steqeyma nabs FDA approval as seventh Stelara biosimilar

Celltrion's Steqeyma nabs FDA approval as seventh Stelara biosimilar

The FDA has approved the Stelara biosimilar Steqeyma for the treatment of adults and children with plaque psoriasis and psoriatic arthritis and adults with Crohn’s disease and ulcerative colitis, Celltrion announced in a press release.

SPONSORED CONTENT
December 18, 2024
45 min listen
Save

How GIs can recapture GI with Larry Kosinski, MD

How GIs can recapture GI with Larry Kosinski, MD

In this podcast episode, Larry Kosinski, MD, founder of SonarMD, discusses reclaiming GI services for patients and physicians, developing new tools for IBD patients and more.

SPONSORED CONTENT
December 04, 2024
2 min read
Save

AGA updates living guideline on pharmacological management of moderate to severe UC

AGA updates living guideline on pharmacological management of moderate to severe UC

In light of a “significant expansion in the therapeutic armamentarium” for moderate to severe ulcerative colitis, the AGA has released an updated living clinical practice guideline of patient-centered pharmacological interventions.

SPONSORED CONTENT
December 03, 2024
2 min read
Save

Concomitant use of common medications does not significantly affect UC induction therapy

Concomitant use of common medications does not significantly affect UC induction therapy

Baseline concomitant exposure to commonly used medications, such as corticosteroids and 5-aminosalicylates, did not significantly affect clinical and endoscopic outcomes during induction therapy in ulcerative colitis, data analysis showed.

SPONSORED CONTENT
December 02, 2024
1 min read
Save

FDA approves Yesintek, sixth Stelara biosimilar; launch slated for February

FDA approves Yesintek, sixth Stelara biosimilar; launch slated for February

The FDA has approved the Stelara biosimilar Yesintek for indications matching the reference product, with a commercial launch date expected for early 2025, according to a press release from Biocon Biologics.

SPONSORED CONTENT
November 15, 2024
5 min watch
Save

VIDEO: Subcutaneous guselkumab induction achieves clinical remission in Crohn’s disease

VIDEO: Subcutaneous guselkumab induction achieves clinical remission in Crohn’s disease

PHILADELPHIA — Subcutaneous guselkumab outperformed placebo and, as with IV administration, appears to have “profound induction effects” on both clinical remission and endoscopic response in Crohn’s disease, a presenter told Healio.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails